Jones Trading Begins Coverage on Septerna (NASDAQ:SEPN)

Analysts at Jones Trading assumed coverage on shares of Septerna (NASDAQ:SEPN) in a research note issued to investors on Tuesday,Benzinga reports. The firm set a “buy” rating and a $43.00 price target on the stock. Jones Trading’s target price would suggest a potential upside of 45.42% from the company’s previous close.

Several other research analysts have also recently weighed in on SEPN. HC Wainwright increased their price objective on Septerna from $26.00 to $30.00 and gave the stock a “buy” rating in a research report on Tuesday, November 11th. Truist Financial started coverage on shares of Septerna in a research report on Monday, December 15th. They set a “buy” rating and a $34.00 price target on the stock. Cantor Fitzgerald reissued an “overweight” rating and issued a $25.00 price objective on shares of Septerna in a report on Friday, September 5th. Weiss Ratings restated a “sell (d-)” rating on shares of Septerna in a research report on Wednesday, October 8th. Finally, Raymond James Financial began coverage on shares of Septerna in a research report on Friday, December 19th. They issued a “strong-buy” rating and a $38.00 price target for the company. One research analyst has rated the stock with a Strong Buy rating, five have assigned a Buy rating and one has given a Sell rating to the company’s stock. According to MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $33.00.

Septerna Stock Performance

Shares of SEPN opened at $29.57 on Tuesday. The firm has a market cap of $1.32 billion, a P/E ratio of -19.58 and a beta of 3.80. Septerna has a 52 week low of $4.17 and a 52 week high of $30.50. The firm’s 50-day simple moving average is $24.09 and its 200 day simple moving average is $17.32.

Septerna (NASDAQ:SEPN) last issued its quarterly earnings data on Monday, November 10th. The company reported ($0.09) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.19 by ($0.28). Septerna had a negative return on equity of 17.98% and a negative net margin of 266.77%.The firm had revenue of $21.50 million for the quarter, compared to the consensus estimate of $24.50 million. As a group, equities analysts forecast that Septerna will post -7.11 earnings per share for the current year.

Insider Activity

In related news, SVP Daniel D. Long sold 3,501 shares of the stock in a transaction that occurred on Monday, November 10th. The shares were sold at an average price of $18.06, for a total transaction of $63,228.06. Following the sale, the senior vice president owned 92,911 shares in the company, valued at approximately $1,677,972.66. This trade represents a 3.63% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Corporate insiders own 4.30% of the company’s stock.

Institutional Trading of Septerna

Large investors have recently bought and sold shares of the business. Covestor Ltd lifted its holdings in shares of Septerna by 55.8% in the third quarter. Covestor Ltd now owns 3,620 shares of the company’s stock worth $68,000 after acquiring an additional 1,296 shares during the last quarter. JPMorgan Chase & Co. boosted its holdings in shares of Septerna by 15.0% during the 2nd quarter. JPMorgan Chase & Co. now owns 10,101 shares of the company’s stock valued at $107,000 after acquiring an additional 1,315 shares in the last quarter. PharVision Advisers LLC raised its position in Septerna by 17.5% in the third quarter. PharVision Advisers LLC now owns 11,932 shares of the company’s stock valued at $224,000 after purchasing an additional 1,780 shares during the last quarter. Russell Investments Group Ltd. bought a new stake in shares of Septerna during the third quarter worth about $36,000. Finally, BNP Paribas Financial Markets boosted its position in Septerna by 88.0% during the 3rd quarter. BNP Paribas Financial Markets now owns 4,155 shares of the company’s stock worth $78,000 after buying an additional 1,945 shares during the period.

Septerna Company Profile

We are a clinical-stage biotechnology company pioneering a new era of G protein-coupled receptor (GPCR) oral small molecule drug discovery powered by our proprietary Native Complex Platform™. Our industrial-scale platform aims to unlock the full potential of GPCR therapies and has led to the discovery and development of our deep pipeline of product candidates focused initially on treating patients in three therapeutic areas: endocrinology, immunology and inflammation, and metabolic diseases. GPCRs are the largest and most diverse family of cell membrane receptors and regulate physiological processes in nearly every organ system of the human body.